138 related articles for article (PubMed ID: 22430922)
1. Physicochemical performances of indomethacin in cholesteryl cetyl carbonate liquid crystal as a transdermal dosage.
Aeinleng N; Songkro S; Noipha K; Srichana T
AAPS PharmSciTech; 2012 Jun; 13(2):513-21. PubMed ID: 22430922
[TBL] [Abstract][Full Text] [Related]
2. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
3. Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles.
Tahvanainen M; Rotko T; Mäkilä E; Santos HA; Neves D; Laaksonen T; Kallonen A; Hämäläinen K; Peura M; Serimaa R; Salonen J; Hirvonen J; Peltonen L
Int J Pharm; 2012 Jan; 422(1-2):125-31. PubMed ID: 22063301
[TBL] [Abstract][Full Text] [Related]
4. Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods.
Limnell T; Santos HA; Mäkilä E; Heikkilä T; Salonen J; Murzin DY; Kumar N; Laaksonen T; Peltonen L; Hirvonen J
J Pharm Sci; 2011 Aug; 100(8):3294-3306. PubMed ID: 21520084
[TBL] [Abstract][Full Text] [Related]
5. Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies.
Estracanholli EA; Praça FS; Cintra AB; Pierre MB; Lara MG
AAPS PharmSciTech; 2014 Dec; 15(6):1468-75. PubMed ID: 24980082
[TBL] [Abstract][Full Text] [Related]
6. Combination with l-Menthol Enhances Transdermal Penetration of Indomethacin Solid Nanoparticles.
Nagai N; Ogata F; Yamaguchi M; Fukuoka Y; Otake H; Nakazawa Y; Kawasaki N
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31349657
[TBL] [Abstract][Full Text] [Related]
7. Omega 3 fatty acid-enriched nanoemulsion of thiocolchicoside for transdermal delivery: formulation, characterization and absorption studies.
Kumar D; Ali J; Baboota S
Drug Deliv; 2016; 23(2):591-600. PubMed ID: 24892633
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process.
Chun NH; Wang IC; Lee MJ; Jung YT; Lee S; Kim WS; Choi GJ
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):854-61. PubMed ID: 23454054
[TBL] [Abstract][Full Text] [Related]
9. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam.
Al-Mahallawi AM; Abdelbary AA; Aburahma MH
Int J Pharm; 2015 May; 485(1-2):329-40. PubMed ID: 25796122
[TBL] [Abstract][Full Text] [Related]
10. Enhanced release of indomethacin from Pvp/stearic acid microcapsules prepared coupling Co-freeze-drying and ultrasound assisted spray-congealing process.
Cavallari C; Luppi B; Di Pietra AM; Rodriguez L; Fini A
Pharm Res; 2007 Mar; 24(3):521-9. PubMed ID: 17252191
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies.
Kaminska E; Adrjanowicz K; Zakowiecki D; Milanowski B; Tarnacka M; Hawelek L; Dulski M; Pilch J; Smolka W; Kaczmarczyk-Sedlak I; Kaminski K
Pharm Res; 2014 Oct; 31(10):2887-903. PubMed ID: 24831310
[TBL] [Abstract][Full Text] [Related]
12. Microemulsion: a novel transdermal delivery system to facilitate skin penetration of indomethacin.
Chen L; Tan F; Wang J; Liu F
Pharmazie; 2012 Apr; 67(4):319-23. PubMed ID: 22570938
[TBL] [Abstract][Full Text] [Related]
13. Formulation and characterizations of delayed release multi particulates system of indomethacin: optimization by response surface methodology.
Nandy BC; Mazumder B
Curr Drug Deliv; 2014; 11(1):72-86. PubMed ID: 24783236
[TBL] [Abstract][Full Text] [Related]
14. Phase behavior of rifampicin in cholesterol-based liquid crystals and polyethylene glycol.
Gangadhar KN; Changsan V; Buatong W; Srichana T
Eur J Pharm Sci; 2012 Dec; 47(5):804-12. PubMed ID: 23026447
[TBL] [Abstract][Full Text] [Related]
15. Design and evaluation of transdermal drug delivery system for curcumin as an anti-inflammatory drug.
Patel NA; Patel NJ; Patel RP
Drug Dev Ind Pharm; 2009 Feb; 35(2):234-42. PubMed ID: 18785045
[TBL] [Abstract][Full Text] [Related]
16. Effect of cyclohexanone derivatives on in vitro percutaneous absorption of indomethacin.
Danyi Q; Takayama K; Nagai T
Drug Des Deliv; 1989 Jun; 4(4):323-30. PubMed ID: 2775452
[TBL] [Abstract][Full Text] [Related]
17. Development of a new nanovesicle formulation as transdermal carrier: formulation, physicochemical characterization, permeation studies and anti-inflammatory activity.
Gaur PK; Mishra S; Purohit S; Kumar Y; Bhandari A
Artif Cells Nanomed Biotechnol; 2014 Oct; 42(5):323-30. PubMed ID: 23944163
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
[TBL] [Abstract][Full Text] [Related]
19. The in vitro and in vivo indomethacin release from self-setting bioactive glass bone cement.
Otsuka M; Nakahigashi Y; Matsuda Y; Kokubo T; Yoshihara S; Fujita H; Nakamura T
Biomed Mater Eng; 1997; 7(5):291-302. PubMed ID: 9457380
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the physicochemical and biopharmaceutical properties of fluoro-indomethacin.
Mori MM; Airaksinen AJ; Hirvonen JT; Santos HA; Caramella CM
Curr Drug Metab; 2013 Jan; 14(1):80-9. PubMed ID: 22497567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
